Published on: 10 Jul 2014

CYTOBLASTIN Injection (Vinblastine)

Composition

CYTOBLASTIN Injection
Each ml contains
Vinblastine Sulphate IP........................1 mg
Sodium Chloride IP..........................9 mg
Benzyl Alcohol IP.......................0.9% v/v
Water for injection IP ........................q.s.

Indications

In the palliative treatment of the following:

1. Frequently Responsive Malignancies
Generalized Hodgkin's disease (Stages III and IV, Ann Arbor modification of Rye staging system)
Lymphocytic lymphoma (nodular and diffuse, poorly and well differentiated)
Histiocytic lymphoma
Mycosis fungoides (advanced stages)
Advanced carcinoma of the testis
Kaposi's sarcoma
Letterer-Siwe disease (histiocytosis X)
2. Less Frequently Responsive Malignancies
Choriocarcinoma resistant to other chemotherapeutic agents
Carcinoma of the breast, unresponsive to appropriate endocrine surgery and hormonal therapy

Dosage And Administration

Dosage
Adults: Initiate therapy by single intravenous dose of 3.7 mg/m2 of body surface area followed by a simplified and
conservative incremental approach at weekly intervals until maximum dose not exceeding 18.5 mg/m2 bsa is reached.
Paediatric patients: Dose varies depending on the schedule used and whether administered as a single agent or in
combination regimen.
Initial doses reported:
● As a single agent for Letterer-Siwe disease (histiocytosis X): 6.5 mg/m2
● In combination with other chemotherapeutic agents for Hodgkin's disease: 6 mg/m2
● Testicular germ cell carcinomas in a combination regimen: 3 mg/m2

Table: Incremental approach to dosage at weekly intervals

 Adults Children

mg/m mg/m2
2
bsa bsa

First 3.7 2.5

Dose

Second 5.5 3.75

Dose

Third 7.4 5.0

Dose

Fourth 9.25 6.25

Dose

Fifth 11.1 7.5

Dose
Administration
The solution may be injected either directly into the vein or into the injection site of a running intravenous infusion.
Injection of vinblastine sulphate may be completed in about one minute.
FOR INTRAVENOUS USE ONLY - FATAL IF GIVEN BY OTHER ROUTES

Contraindications

● Significant granulocytopenia unless this is a result of the disease being treated.

● Presence of bacterial infections. Such infections must be brought under control prior to the initiation of therapy with vinblastine
sulfate.

Most Common Adverse Reactions

Leucopenia, anaemia, thrombocytopenia, alopecia, paresthesias, constipation, hypertension, malaise, bone pain,
weakness, pain in tumor-containing tissue, dizziness, jaw pain

Storage

Store between 2°C and 8°C in a refrigerator. Do not freeze. Protect from light.

Packaging Information

CYTOBLASTIN Injection : 10 mg/10 ml in a vial

Last updated: May 2013
Last reviewed: May 2013

CYTOBLASTIN Injection
Source URL: https://www.ciplamed.com/content/cytoblastin-injection